Scholars Central

Conference abstractPublished 6 Dec 2018

Preclinical evaluation of the immunogenicity of a new Cuban pneumococcal conjugate vaccine (PCV10) administered concomitantly with Heberpenta®-L vaccine

Authors: Dagmar Garcia Rivera, Yosbany Perez Barrios, Abel Zanuy Reguera, Mabel Hernandez Cedeno, Rocmira Perez Nicado, Yisabel Aranguren Mazorra, Caridad Zayas Vignier, Reinaldo Acevedo Grogues, Annette Villar Aneiros, Yury Valdes Balbin, Darielys Santana Mederos, Vicente Verez Bencomo

Finlay Vaccine Institute in Havana, Cuba

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Finlay Vaccine Institute is developing a new pneumococcal conjugate vaccine (PCV10-TT) against serotypes 1, 5, 6A, 6B, 9V, 14, 18C, 19A, 19F and 23F of Streptococcus pneumoniae, all of them conjugated to tetanus toxoid. Good immunization practices require concomitance studies of new candidates with currently applied vaccines, in addition of immunogenicity studies. The aim of this work was to evaluate the immunogenicity and possible immunological interferences between the concomitant administrations of PCV10- TT with Heberpenta®-L, a DTwP combined vaccine, in the New Zealand rabbit model. Prevnar-13® was used as a control vaccine to compare vs PCV10-TT candidate. Rabbits were immunized concomitantly with three doses of Heberpenta®-L and Prevnar 13® or PCV10-TT. The IgG antibody responses to all antigens were evaluated by immunoenzymatic assays. PCV10-TT was as immunogenic as Prevnar-13 for common serotypes. No interferences were induced by PCV10-TT on the humoral response against the antigens present in the Heberpenta®-L vaccine (p>0.05). The co-administration did not induce a reduction of immune response generated against the pneumococcal polysaccharides contained in PCV10-TT vaccine (p>0.05). The concomitant administration of Heberpenta®-L did not induce interference on Prevnar-13® antigens. The PCV10-TT response behaved similar to the Prevnar 13® vaccine when they were applied concomitantly with Heberpenta®-L. The preclinical results suggest that PCV10-TT is as immunogenic as Prevnar-13 for common serotypes, ant it will not interfere with the immune response induced by the licensed Heberpenta-L® vaccine.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Immunome Research.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalImmunome Research
  • SubjectImmunology & Microbiology
  • BylineArticles whose byline prints “Dagmar Garcia Rivera”
  • BylineArticles whose byline prints “Yosbany Perez Barrios”
  • BylineArticles whose byline prints “Abel Zanuy Reguera”
  • BylineArticles whose byline prints “Mabel Hernandez Cedeno”
  • BylineArticles whose byline prints “Rocmira Perez Nicado”
  • BylineArticles whose byline prints “Yisabel Aranguren Mazorra”
  • BylineArticles whose byline prints “Caridad Zayas Vignier”
  • BylineArticles whose byline prints “Reinaldo Acevedo Grogues”